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Computed Tomography and Magnetic Resonance
Findings of Fat-Poor Angiomyolipomas
Aaron M. Potretzke, MD,1 Theodora A. Potretzke, MD,2 Tyler M. Bauman, BS,1 B. Alexander Knight, MD,1
Alyssa M. Park, MD,1 Jonathan M. Mobley, MD,1 Robert Sherburne Figenshau, MD,1 and Cary Lynn Siegel, MD3
ABSTRACT
Introduction: Approximately 5% of angiomyolipomas (AMLs) are classified as ‘‘fat poor’’ due to lack of visually
detectable fat on imaging, making them difficult to distinguish from renal cell carcinoma. Recent investigations
have proposed CT and MR imaging features suggestive of fat-poor AML (fp-AML). Herein, we determined the
frequency of these features in a cohort of fp-AMLs by retrospective review of preoperative imaging.
Methods: A pathology database query from January 2005 to August 2013 identified 49 renal specimens of AML
with available imaging. A retrospective review of all CT and MR images of these 49 cases was conducted.
Cases with visually detectable fat on imaging were excluded.
Results: A total of 26 fp-AMLs were identified. Thirteen lesions had available unenhanced CT images, of which
eight (62%) were hyperdense compared to the adjacent renal parenchyma, while five (38%) were isodense.
Twenty lesions had enhanced CT images: 14 (70%) and 6 (30%) with homogeneous and heterogeneous
enhancement, respectively. Of the nine lesions with enhanced MR sequences, five (56%) were homogeneously
enhancing, and four (44%) were heterogeneously enhancing. Eight of nine (89%) lesions had hypointense signal
intensity (SI) on T2-weighted MR sequences, while one (11%) had hyperintense SI. None of the eight lesions
displayed a decrease in signal on fat-suppressed sequences.
Conclusions: In this study, we confirmed common imaging features of fp-AML: high attenuation on un-
enhanced CT sequences, homogeneous enhancement on CT, and hypointensity on T2-weighted MR. When
these features are present, a renal mass biopsy may be prudent.
Keywords: angiomyolipoma, computed tomography, diagnosis, magnetic resonance, small renal mass
Introduction
Renal angiomyolipoma (AML) represents a relativelyrare, benign neoplasm; its prevalence has been reported
to be between 0.1% and 2.2%.1,2 While large (i.e., >4 cm)
and symptomatic lesions warrant intervention, smaller le-
sions are observed.3 Distinguishing AML from renal cell
carcinoma (RCC) typically depends on the presence of
macroscopic fat. However, *4.5% of AMLs lack visually
detectable fat on imaging and are therefore considered fat-
poor AMLs (fp-AMLs).4,5 The difficulty in distinguishing
these benign lesions from RCC has resulted in unnecessary
surgeries, as 8.1% to 32.6% of partial nephrectomies are
done for benign disease, with AMLs being found in 18.5%
to 43.5% of these cases.5–8
Improved radiographic identification of fp-AML could
reduce surgeries undertaken for suspicion of malignancy.
The CT and MR characteristics of fp-AML have been eval-
uated in several series, although the reliable distinction of
these lesions remains elusive.4 The objective of this investi-
gation was to evaluate the CT and MR characteristics of
pathologically proven fp-AMLs, to identify findings that may
suggest AML in otherwise ambiguous cases.
Materials and Methods
Patient and pathologic data
After institutional review board approval, a query of the
pathology database for AMLs was conducted from January 1,
2005, to August 1, 2013, and these cases were evaluated for
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available preoperative imaging. Forty-nine patients had path-
ologically proven AML and available imaging. Patients were
excluded who had visually detectable fat on imaging (n= 17)
or lesions too small (<3mm) to evaluate on preoperative CT or
MR (n= 6). The final cohort consisted of 26 patients, all with
single tumors.
Demographic and medical history was recorded, including
age, gender, medical history, and source of pathologic speci-
men. Further pathologic descriptions, such as the predomi-
nance of smooth muscle or scant fatty component, were
recorded. The percentage of fat was not specified in the pa-
thology report.
Computed tomography
Twenty of the 26 patients underwent a preoperative CT
examination. Fifteen CTs were performed at our institution,
while six were acquired at outside institutions. Due to the
retrospective nature of the study and the inclusion of outside
imaging, CT acquisition parameters and protocols were not
standardized. One patient underwent two preoperative CT
examinations (one with corticomedullary phase only and one
with pre- and postcontrast images); therefore, the results of 21
preoperative CTs are presented. All patients had postcontrast
imaging available in the corticomedullary phase (n= 8), the
nephrographic phase (n= 4), or both (n= 9). Thirteen patients
had precontrast imaging available, and three studies included
an excretory phase.
Magnetic resonance
Nine of the 26 patients underwent MR examinations (6
MR only, 3 MR in addition to CT). Due to the retrospective
nature of the study, MR acquisition parameters and protocols
were not standardized. Seven studies were performed at our
institution, while two were acquired at outside institutions.
All nine MR examinations included T2-weighted and
postcontrast sequences. Eight MR examinations included
fat-suppressed sequences (both in- and opposed-phase and
fat-saturated sequences). Eight MRs included unenhanced,
corticomedullary, and nephrographic phases, with five of
eight having additional delayed postcontrast phases. One
MR was performed only with unenhanced and nephro-
graphic phases.
Image analysis
All CT and MR images were reviewed by one fellowship-
trained radiologist (C.S.) with 20 years of experience in gen-
itourinary imaging. Tumor diameter, side, and tumor location
(upper pole, interpolar, or lower pole) were recorded. Tumors
were labeled exophytic, endophytic, or central. Exophytic le-
sions were further assessed to see if the lesion was entirely
exophytic, possessed a round or angular tumor/parenchymal
interface, or a ‘‘mushroom’’ extension from the renal border
(Fig. 1).9,10 The presence or absence of calcifications and ne-
crosis on CT and necrosis on MR was recorded. For both CT
and MR examinations, manually placed regions of interest
(ROIs) on the slice with largest volume of tumor were used for
density, signal intensity (SI), and enhancement assessment.
Homogeneity of enhancement was assessed by gross visual
inspection.
FIG. 1. Examples of radiographic features evaluated in all
patients with AML: (a) complete exophytic lesion, (b) an-
gular interface between tumor and normal renal paren-
chyma, and (c) mushroom-shaped extension beyond the
renal border. AML = angiomyolipoma.














































CT attenuation was quantitatively measured for renal mas-
ses on all phases. Enhancement was defined as an increase in
attenuation of 10 HU from the unenhanced to enhanced se-
quences (either corticomedullary or nephrographic). The at-
tenuation of the tumor was visually compared to the normal
renal parenchyma on the unenhanced scans and described as
hypodense, isodense, or hyperdense.
OnMR, the SI in the tumor on T1- and T2-weighted images
was described visually as hypointense, isointense, or hyper-
intense relative to the adjacent normal renal parenchyma. SI is
an arbitrary unit that depends on numerous factors specific to
both patient and MRI scanner.11 These variables include in-
trinsic properties of T1 and T2 sequences, echo time, inver-
sion time, and rotational angle. The tumor SI on in- and
opposed-phase images was recorded with ‘‘SI drop,’’ defined
as a 10% drop in SI from in-phase to opposed-phase. Lesion
SI was measured at the same slice level on in-phase and
opposed-phase images with a manually placed round or el-
liptical ROI. SI values were compared between the two, and a
quantitative calculation to assess for signal drop in the op-
posed phase was performed using the following formula:
(SIin-SIopp)/SIin· 100, where SIn is lesion SI on in-phase
images and SIopp is lesion SI on opposed-phase images. The
threshold of 10% was chosen to reflect a non-negligible
amount of intralesional microscopic fat and to be consistent
with prior literature.12 The SI on fat saturation sequences was
visually compared to the same sequence without fat satura-
tion, and the tumor was noted to have or not havemacroscopic
fat. Quantitative measurements of SI were obtained in each
phase. Enhancement was defined as an increase in SI of 10%
from precontrast to nephrographic sequences and by using the
following equation: % enhancement= (SIpost-SIpre)/SIpre·
100%, where SIpre is the precontrast SI of the lesion and SIpost
is the postcontrast SI of the lesion. A 10% threshold was used
to achieve high sensitivity for tumor enhancement and si-
multaneously avoid artifactual enhancement as can be seen in
nonenhancing lesions (e.g., simple cysts may manifest en-
hancement of 1%–5%).11
Descriptive statistics were performed, rather than a formal
statistical analysis, given that the aim of the study was to
determine frequency of findings.
Table 1. Patient and Gross Tumor Characteristics
Characteristic
Total number of patients 26
Age


















Mean cm– SD 1.9 – 1.0





Upper pole 11 (42)
Interpolar 8 (31)








Mushroom shape/angular interface (%)
Yes 5 (19)
No 21 (81)
SD = standard deviation.
Table 2. CT Characteristics of Angiomyolipoma
with Minimal Fat





















Attenuation at each phase Mean – SD
Number
of CT scans
Unenchanced, HU 37– 10 13
Corticomedullary, HU 116 – 38 17
Nephrographic, HU 90– 27 13
Delayed, HU 55– 18 3
Enhancement from unenhanced to
Corticomedullary, HU 80– 45 8
Nephrographic, HU 53– 32 10
















































Twenty-three patients were found to have fp-AML after
undergoing a partial nephrectomy, while one patient was
diagnosed after radical nephrectomy. Two patients were di-
agnosed by renal mass biopsy, one of which was performed at
the time of cryoablation for suspected RCC. Table 1 sum-
marizes the patients’ clinical characteristics. One patient had
a history of AML and was also the only patient with tuberous
sclerosis. Table 1 also displays radiographic characteristics
of the AMLs. Twenty-four of the AMLs were less than 4 cm,
leaving only 2 AMLs greater than 4 cm in diameter (4.2 and
5.3 cm, respectively).
Review of pathology reports revealed a specific descrip-
tion of ‘‘minimal fat,’’ ‘‘fat-poor,’’ or similar terms for 12 of
the masses. The remaining 14 masses were identified as being
fp-AMLs by the pathologic identification of AML and com-
parison to the preoperative imaging, which did not reveal
macroscopic fat. One tumorwas the epithelioid variant of AML.
Table 2 summarizes the CT findings of the 20 patients who
underwent CT examination. The mean – standard deviation
(SD) density on unenhanced images was 37– 10 HU. The
range was from 20 to 54 HU, and no lesions had HU mea-
surements near the -10 HU threshold, which is characteristic
of fat.13 All 13 patients with unenhanced and enhanced se-
quences demonstrated enhancement. Figure 2 illustrates the
unenhanced and enhanced CT features of the majority of
fp-AMLs.
Table 3 shows theMR characteristics of nine AML lesions.
The mean SI – SD on T1-weighted images before gadolinium
was 113 (–73). Enhancement following administration of
gadolinium occurred in all cases with available pre- and
postgadolinium images. All nine lesions were either hy-
pointense on T2-weighted MR or homogenously enhancing.
Figure 3 illustrates common MR features of fp-AMLs.
Discussion
Differentiating an fp-AML from RCC remains challeng-
ing, despite improvements in imaging.4,10 The body of lit-
erature describing findings and techniques that may be used
to distinguish fp-AMLs is growing (Table 4). Some of the
FIG. 2. Transverse CT scan showing a 1.8 cm exophytic,
left lower pole AML with minimal fat in a 41-year-old fe-
male (arrows). (a) The mass displays hyperattenuation (41
Hounsfield units) compared to the normal renal parenchyma
on unenhanced CT. (b) The mass exhibits homogeneous
enhancement (64 Hounsfield units) in the nephrographic
phase. CT= computed tomography.
Table 3. MR Characteristics of Angiomyolipoma
with Minimal Fat
Characteristic Number Percentage (%)








In- and opposed-phase SI drop (N= 8)
Yes 2 25
No 6 75
Fat saturation (N = 8)
Yes 0 0
No 8 100
Enhancement pattern (N= 9)
Homogeneous 5 56
Heterogeneous 4 44
Necrosis (N = 9)
Yes 0 0
No 9 100
T2 hypointense or homogeneous enhancement (N= 9)
Yes 9 100
No 0 0
Characteristic Mean – SD
Number
of MR sequences
Unenhanced T1 SI 113 – 73 9
Corticomedullary T1 SI 227 – 105 8
Nephrographic T1 SI 229 – 122 9
Delayed T1 SI 242 – 65 5
Enhancement from unenhanced to
Corticomedullary 134 – 68 8
Nephrographic 108 – 65 9
SI= signal intensity.














































most commonly described findings are (1) hyperdensity on
unenhanced CT, (2) homogenous enhancement on enhanced
CT, and (3) hypointensity of T2-weighted MR.We evaluated
the applicability of these imaging characteristics to an insti-
tutional cohort of fp-AMLs. Twenty-one of 26 (81%) patients
met at least one of the criteria: hyperattenuation on un-
enhanced CT (8/13 [62%]), homogeneous enhancement on
CT (14/20 [70%]), or hypointensity on T2-weighted MR (8/9
[89%]). Other notable findings in the present review include
the absence of a signal drop on opposed-phase MR (6/8
[75%]) and homogenous enhancement on enhanced MR (5/9
[56%]). However, these characteristics are not as often de-
tailed in the literature, and may not help distinguish fp-AML
from RCC.12,14
As in the present study, many previous studies have found
that hyperintensity on unenhanced CT10,12,15–18 and ho-
mogenous enhancement on contrasted CT4,10,15,17 can help
to identify fp-AMLs (Table 4). Similarly, there are several
reports that describe a hypointense signal for fp-AMLs on
T2-weighted MR.5,12,14,19–22 In a 2016 investigation, Jeong
et al. compared 18 fp-AMLs to 155 RCCs. The authors
found that the fp-AMLs had an increased tumor–cortex at-
tenuation ratio on unenhanced CT and had a decreased SI of
T2-weighted MR.12 Likewise, in another large series de-
scribed by Yang et al., 33 fp-AMLs were compared to 102
RCC tumors. The fp-AMLs were found to have a signifi-
cantly greater rate of unenhanced attenuation of >38.5 HU
and enhanced homogeneity.17 Still other findings have been
associated with fp-AML. Renal masses, which have been
described as having either an angular interface with the
adjacent parenchyma or having a shape resembling an ‘‘ice-
cream cone’’ or ‘‘mushroom,’’17,23 are more likely to be fp-
AML (Fig. 1). Finally, some authors have proposed using
positron emission tomography-CT, which has shown early
promising results.24
Despite the above imaging descriptions, the findings
manifest in fp-AMLs can be inconsistent across studies
(Table 4). For example, MRwith diffusion-weighted imaging
presents conflicting results, as one study found a greater ap-
parent diffusion coefficient (ADC)25 and another a lower
ADC relative to RCC.26 Also, some authors have reported
that in- and opposed-phase MR can be utilized to distinguish
fp-AMLs,14 while others have found these sequences unre-
liable.12,21,27 Furthermore, the use of CT histogram analysis
to predict fp-AML has been met with conflicting results and
is not readily utilized.13,28,29 Finally, while ultrasound pro-
vides characteristic findings (i.e., hyperechogenicity) for
lipid-rich AMLs, the ultrasonic findings for fp-AML are
variable. In the present cohort, seven patients had ultrasounds
available for interpretation. Four of the fp-AMLs were hy-
perechoic, while three were hypoechoic.
The differing quantity of fat in each tumor makes universal
findings on imaging unlikely. Thus, it is most likely that no
single finding or instrument will be perfectly accurate. Recent
work by Kim et al. has suggested a more comprehensive
scoring system, which includes both clinical and radio-
graphic variables. The scoring system was able to yield an
area under the curve of 0.919. At various cutoff points, the
system conferred accuracy, sensitivity, and specificity as high
as 90%, 68%, and 95%, respectively.15 Including multiple
variables in such a system is time-consuming, not easily
calculable, and presents challenges in any health system, in
which imaging protocols are not standardized.
The rate of benign tumor extirpation remains unsatisfac-
tory, and one of the most common benign lesions excised is
AML.5–8 Thus, improved diagnostic practices are necessary.
The use of percutaneous biopsy in patients with small renal
masses may augment the effectiveness of current manage-
ment of small renal masses. Contemporary biopsy techniques
afford yields of >80% to 90%, benignity versus malignancy
accuracy of 74% to 100%, and complications rates of 1%
to 2%.30 Given the safety and accuracy profiles of renal
biopsy, it is reasonable to assert that a biopsy should be
undertaken in any patient with a radiographic indication of
FIG. 3. Transverse MR images
showing a 1.1 cm right upper pole
AML with minimal fat in a 77-
year-old female (arrows). (a) T1-
weighted sequence illustrating an
isointense mass. (b) T1-weighted
sequence following gadolinium in-
jection illustrates homogenous en-
hancement. (c) T2-weighted
sequence displaying intratumor




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































possible benignity, or for any patient for whom the man-
agement may change based on biopsy results.
There are limitations to the present study, many of which
are attributable to its retrospective nature. First, there was
variability present in the imaging protocols. Furthermore, the
series of cases is small, although there are few series with a
larger cohort of fp-AMLs. A number of AMLs were not in-
cluded in the present description due to the lack of available
outside imaging. Also, diffusion-weighted MR imaging and
CT histogram analysis were not available for many of the
patients in this cohort, making comparison to the findings of
previous reports impossible. In addition, all of the imaging was
interpreted by a single, genitourinary-dedicated, fellowship-
trained radiologist; however, she was not blinded to the di-
agnosis of fp-AML. Importantly, the present cohort was not
matched to a group of similar non-fp-AMLs (e.g., RCCs),
which prohibits statistical conclusions. Future work on fp-
AMLs should seek to standardize imaging protocols and in-
crease patient cohorts through multi-institutional collabora-
tions. Finally, future investigations may benefit from focus on
the inclusion of clinical variables (e.g., female gender) and
novel techniques to improve the prospective identification
of fp-AMLs.
Conclusion
The distinction between fp-AML and RCC continues to be
difficult and may result in unnecessary interventions for these
benign lesions. In this series, the majority of fp-AMLs were
found in young females with asymptomatic, small renal
masses. The presence of a small renal mass with hyper-
attenuation compared to normal renal parenchyma on un-
enhanced CT, homogeneous enhancement on enhanced CT,
and a hypointense SI compared to normal renal parenchyma
on T2-weightedMR should raise the suspicion of an fp-AML.
Performing a renal mass biopsy when these features are
present may confirm the diagnosis of AML and prevent un-
necessary treatment of these benign tumors.
Author Disclosure Statement
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ADC ¼ apparent diffusion coefficient
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AUC ¼ area under the curve
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CT ¼ computed tomography
fp-AML ¼ fat-poor angiomyolipoma
HU ¼ Hounsfield units
MR ¼ magnetic resonance
RCC ¼ renal-cell carcinoma
ROC ¼ receiver operating characteristic
ROI ¼ region of interest
SI ¼ signal intensity
SIin ¼ lesion signal intensity on in-phase images
SIopp ¼ lesion signal intensity on opposed-phase images
SIpost ¼ postcontrast signal intensity
SIpre ¼ precontrast signal intensity
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